Apyx Medical Corp

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

APYX$2.94+0.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations for the three

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

Three Months EndedJune 30, · Six Months EndedJune 30,
2024 · 2023 · 2024 · 2023
Sales	$12,149		$13,569		$22,393		$25,711
Cost of sales	4,656		4,290		8,951		8,859
Gross profit	7,493		9,279		13,442		16,852
Other costs and expenses:
Research and development	1,424		1,357		2,821		2,628
Professional services	2,096		1,594		3,670		3,334
Salaries and related costs	4,682		4,877		9,378		9,795
Selling, general and administrative	4,838		5,378		9,735		10,633
Total other costs and expenses	13,040		13,206		25,604		26,390
Gain on sale-leaseback	—		2,692		—		2,692
Loss from operations	(5,547)		(1,235)		(12,162)		(6,846)
Interest income	439		179		934		230
Interest expense	(1,427)		(543)		(2,823)		(777)
Other (expense) income, net	(1)		646		(22)		641
Total other (expense) income, net	(989)		282		(1,911)		94
Loss before income taxes	(6,536)		(953)		(14,073)		(6,752)
Income tax expense (benefit)	50		66		103		(2,201)
Net loss	(6,586)		(1,019)		(14,176)		(4,551)
Net loss attributable to non-controlling interest	(30)	(25)		(44)		(74)
Net loss attributable to stockholders	$(6,556)		$(994)		$(14,132)		$(4,477)
Loss per share:
Basic and diluted	$(0.19)		$(0.03)		$(0.41)		$(0.13)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.